Bibliographic Details
| Title: |
Switching from ustekinumab originator to biosimilar: No adverse impact on inflammatory bowel disease control and well tolerated by patients in a UK multicentre study. |
| Authors: |
Sharma, E.1, Allah-Ditta, M.2, Povlsen, S.3, Greenwood, J.1, Shinh, S.1, Omrani, F.1, Raftis, K.1, Leason, G.1, Rousseau, C.1, Cattermull, M.1, Leung, N.1, Sonwalkar, S.4, Toft, J.5, Rees, F.6, Aslam, A.6, Rashid, Z.7, Rudling, R.8, Kwok, J.9, Tavangari, Y.9, Kirkbride, M.9 |
| Source: |
Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi2723-i2725. 3p. |
| Database: |
Academic Search Ultimate |
